Foghorn Therapeutics Inc. Marketable Securities, Unrealized Gain (Loss)
Foghorn Therapeutics Inc. (FHTX) reported Marketable Securities, Unrealized Gain (Loss) of -$111.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-03-11
- Foghorn Therapeutics Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was $0.00.
- Foghorn Therapeutics Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $68.00K, a 90.26% decline year-over-year.
- Foghorn Therapeutics Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-06-30 was -$58.00K, a 136.48% decline year-over-year.
- Foghorn Therapeutics Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-03-31 was -$121.00K, a 136.78% decline year-over-year.
- Foghorn Therapeutics Inc. marketable securities, unrealized gain (loss) for fiscal 2025 was -$111.00K, a 111.55% decline from fiscal 2024.
- Foghorn Therapeutics Inc. marketable securities, unrealized gain (loss) for fiscal 2024 was $961.00K, a 69.59% decline from fiscal 2023.
- Foghorn Therapeutics Inc. marketable securities, unrealized gain (loss) for fiscal 2023 was $3.16M.
- Foghorn Therapeutics Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was -$3.98M.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-03-11 | $68.00K derived: sum of 2 quarters · filed 2026-03-11 | $10.00K derived: sum of 3 quarters · filed 2026-03-11 | -$111.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $68.00K 10-Q · filed 2025-11-05 | $10.00K derived: sum of 2 quarters · filed 2025-11-05 | -$111.00K derived: sum of 3 quarters · filed 2025-11-05 | |
| 2025-06-30 | -$58.00K 10-Q · filed 2025-11-05 | -$179.00K derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2025-03-31 | -$121.00K 10-Q · filed 2025-11-05 | |||
| 2024-12-31 | $961.00K 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $698.00K 10-Q · filed 2025-11-05 | $857.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.19M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $159.00K 10-Q · filed 2025-11-05 | $488.00K derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $329.00K 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $3.16M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $826.00K 10-Q · filed 2024-11-04 | $977.00K derived: sum of 2 quarters · filed 2024-11-04 | $2.09M derived: sum of 3 quarters · filed 2024-11-04 | |
| 2023-06-30 | $151.00K 10-Q · filed 2024-11-04 | $1.27M derived: sum of 2 quarters · filed 2024-11-04 | ||
| 2023-03-31 | $1.12M 10-Q · filed 2024-11-04 | |||
| 2022-12-31 | -$3.98M 10-K · filed 2024-03-07 | |||
| 2022-09-30 | -$1.68M 10-Q · filed 2023-11-02 | -$3.67M derived: sum of 2 quarters · filed 2023-11-02 | -$4.85M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | -$2.00M 10-Q · filed 2023-11-02 | -$3.18M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | -$1.18M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | -$3.00K 10-K · filed 2023-03-09 | |||
| 2021-09-30 | -$3.00K 10-Q · filed 2021-11-09 | -$19.00K derived: sum of 2 quarters · filed 2021-11-09 | -$6.00K derived: sum of 3 quarters · filed 2021-11-09 | |
| 2021-06-30 | -$16.00K 10-Q · filed 2021-11-09 | -$3.00K derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2021-03-31 | $13.00K 10-Q · filed 2021-11-09 | |||
| 2020-12-31 | -$7.00K 10-K/A · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |